Cumberland Pharmaceuticals (CPIX) Stock Overview
A specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CPIX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Cumberland Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.11 |
| 52 Week High | US$6.27 |
| 52 Week Low | US$1.85 |
| Beta | -0.33 |
| 1 Month Change | -1.58% |
| 3 Month Change | -37.17% |
| 1 Year Change | -22.83% |
| 3 Year Change | 58.67% |
| 5 Year Change | 2.30% |
| Change since IPO | -81.52% |
Recent News & Updates
Recent updates
Little Excitement Around Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Revenues As Shares Take 31% Pounding
Feb 06
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Shares Fly 26% But Investors Aren't Buying For Growth
Dec 11Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?
Nov 30Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S No Reason For Excitement
Oct 08Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Not Doing Enough For Some Investors As Its Shares Slump 50%
Jun 27Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?
Jun 21Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 30%
May 13Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 117%
Mar 01Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?
Feb 21Improved Revenues Required Before Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Stock's 26% Jump Looks Justified
Jan 15Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Nov 04Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Mar 07Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift Shares
Jan 09Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S
Oct 02Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Aug 10Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?
Mar 18Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Nov 02Calculating The Fair Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)
Jul 20Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Apr 15Checking In On Cumberland Pharmaceuticals
Jan 04Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?
Nov 09Shareholder Returns
| CPIX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.9% | 0.7% | 3.4% |
| 1Y | -22.8% | 43.5% | 29.7% |
Return vs Industry: CPIX underperformed the US Pharmaceuticals industry which returned 37.6% over the past year.
Return vs Market: CPIX underperformed the US Market which returned 25.7% over the past year.
Price Volatility
| CPIX volatility | |
|---|---|
| CPIX Average Weekly Movement | 10.8% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: CPIX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CPIX's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 93 | A. Kazimi | www.cumberlandpharma.com |
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis.
Cumberland Pharmaceuticals Inc. Fundamentals Summary
| CPIX fundamental statistics | |
|---|---|
| Market cap | US$46.96m |
| Earnings (TTM) | -US$2.84m |
| Revenue (TTM) | US$44.52m |
Is CPIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CPIX income statement (TTM) | |
|---|---|
| Revenue | US$44.52m |
| Cost of Revenue | US$6.67m |
| Gross Profit | US$37.85m |
| Other Expenses | US$40.69m |
| Earnings | -US$2.84m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 85.02% |
| Net Profit Margin | -6.37% |
| Debt/Equity Ratio | 21.4% |
How did CPIX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/09 15:26 |
| End of Day Share Price | 2026/04/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cumberland Pharmaceuticals Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| David Windley | Jefferies LLC |
| Marc Goodman | UBS Investment Bank |